Trials / Completed
CompletedNCT00059722
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (planned)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 | |
| DRUG | Placebo | |
| DRUG | ZD1839 |
Timeline
- Start date
- 2003-05-01
- Completion
- 2007-06-01
- First posted
- 2003-05-05
- Last updated
- 2016-08-24
Locations
48 sites across 6 countries: United States, Argentina, Belgium, Germany, South Africa, United Kingdom
Source: ClinicalTrials.gov record NCT00059722. Inclusion in this directory is not an endorsement.